Evaluation of the Antitumor Effects of BPR1J-340, a Potent and Selective FLT3 Inhibitor, Alone or in Combination with an HDAC Inhibitor, Vorinostat, in AML Cancer

Overexpression or/and activating mutation of FLT3 kinase play a major driving role in the pathogenesis of acute myeloid leukemia (AML). Hence, pharmacologic inhibitors of FLT3 are of therapeutic potential for AML treatment. In this study, BPR1J-340 was identified as a novel potent FLT3 inhibitor by...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Wen-Hsing, Yeh, Teng-Kuang, Jiaang, Weir-Torn, Yen, Kuei-Jung, Chen, Chun-Hwa, Huang, Chin-Ting, Yen, Shih-Chieh, Hsieh, Shu-Yi, Chou, Ling-Hui, Chen, Ching-Ping, Chiu, Chun-Hsien, Kao, Li-Chun, Chao, Yu-Sheng, Chen, Chiung-Tong, Hsu, John T.-A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885398/
https://www.ncbi.nlm.nih.gov/pubmed/24416160
http://dx.doi.org/10.1371/journal.pone.0083160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885398/
https://www.ncbi.nlm.nih.gov/pubmed/24416160
http://dx.doi.org/10.1371/journal.pone.0083160

Ejemplares similares